Navigation Links
Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development
Date:5/20/2009

MORRISVILLE, N.C., May 20 /PRNewswire/ --Asymchem Laboratories, Inc., a leading research-based contract manufacturer of API's, intermediates and Drug Products to the pharmaceutical industry, with sites in the U.S. and China, is pleased to announce the recent addition of Dr. Chris Huber as Director of Chemical Development.

Dr. Huber brings to the table over 15 years experience in the pharmaceutical industry (early and late stage), developing process technology for API manufacturing of small molecules. Prior to Asymchem, Dr. Huber directed early phase projects for API manufacturing at Achaogen Inc. and Arena Pharmaceuticals. Much of his career was spent in Pfizer and legacy companies in process chemistry, with focus on optimization, characterization and validation of Phase 3 processes in preparation for commercial manufacturing of API.

As Director of Chemical Development, Dr. Huber will help expand and strengthen Asymchem's pilot scale-up, tech transfers and production efforts into commercial manufacturing. He will report directly to Dr. Jim Gage, VP of Chemical Development.

"I am very pleased to have Dr. Huber on board to help expand and strengthen Asymchem's already well-established large scale manufacturing services," states Dr Hao Hong, CEO of Asymchem. "With his broad experience in the pharmaceutical industry and proven track record of API manufacturing, I am confident that our commercial capabilities will be further strengthened and solidified."

Dr. Huber received his B.S. and M.S. at the Universitat Regensburg , Germany under the supervision of Professors Dr. Henri Brunner, Dr. Jurgen Sauer and Dr. Josef Barthel. He earned his Ph.D. in Organic Chemistry and Catalysis from the Universitat Regensburg, Germany with Professor Dr. Henri Brunner. He did his post doc at Purdue University, Indiana under Professor Thomas Bein on the development of supported organometallic catalysts with application in organic synthesis.

Asymchem Laboratories is a leading research-based contract manufacturer specialized in the development and compliant manufacturing (Contract Research and Manufacturing Services) of API's and Drug Products serving the pharmaceutical industry. With a 14yr track record, Asymchem is committed to the highest level of quality and excellence in the integrated CMC services arena. For further information, please visit the Asymchem website at www.asymchem.com.


'/>"/>
SOURCE Asymchem Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
2. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
3. VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer
4. Christopher and Dana Reeve Foundation Response to FDA Clearance of Gerons Clinical Trial
5. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
6. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
7. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
8. Christine Poon Will Keynote MichBio Expo
9. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
10. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
11. Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)...  At the 2017 Health Information Management Systems ... , IBM (NYSE: IBM ) today introduced ... President and CEO Ginni Rometty will ... 8:30-10 am ET, broadcast live on www.ibm.com ... examine the advent of the Cognitive Era and ...
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... DUBLIN , Feb 17, 2017 Research ... Global Strategic Business Report" report to their offering. ... The report provides separate ... Europe , and Rest of World. Annual estimates and ... six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/23/2017)... 2017  The latest mobile market research from Acuity ... dramatically. The quarterly average price of a biometric smartphone ... Q4 2016.  There are now 120 sub-$150 models on ... from just 28 a year ago at an average ... Maxine Most , Acuity Market Intelligence Principal, "Biometric Smartphones ...
Breaking Biology News(10 mins):